Faculty, Staff and Student Publications

Publication Date

2-6-2025

Journal

The Oncologist

Abstract

Lung cancer is the leading cause of cancer death in the US and globally. The mortality from lung cancer has been declining, due to a reduction in incidence and advances in treatment. Although recent success in developing targeted and immunotherapies for lung cancer has benefitted patients, it has also expanded the complexity of potential treatment options for health care providers. To aid in reducing such complexity, experts in oncology convened a conference (Bridging the Gaps in Lung Cancer) to identify current knowledge gaps and controversies in the diagnosis, treatment, and outcomes of various lung cancer scenarios, as described here. Such scenarios relate to biomarkers and testing in lung cancer, small cell lung cancer, EGFR mutations and targeted therapy in non-small cell lung cancer (NSCLC), early-stage NSCLC, KRAS/BRAF/MET and other genomic alterations in NSCLC, and immunotherapy in advanced NSCLC.

Keywords

Humans, Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Immunotherapy, ErbB Receptors, Mutation, Molecular Targeted Therapy, Biomarkers, Tumor, clinical decision-making, controversies, unanswered questions, lung cancer diagnosis, lung cancer treatment, lung cancer management

DOI

10.1093/oncolo/oyae228

PMID

39237103

PMCID

PMC11883156

PubMedCentral® Posted Date

9-5-2024

PubMedCentral® Full Text Version

Post-print

Published Open-Access

yes

Share

COinS
 
 

To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.